Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cabazitaxel + cisplatin
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Cabazitaxel + cisplatin is a combination of two chemotherapeutic agents used in the treatment of advanced or metastatic solid tumors, particularly when standard therapies have failed. Cabazitaxel is a second-generation semisynthetic taxane that acts as a microtubule inhibitor by binding to beta-tubulin and stabilizing microtubules, thereby preventing cell division and inducing tumor cell death[1][2]. Cisplatin is a platinum-based alkylating agent that forms DNA crosslinks, leading to apoptosis and inhibition of cancer cell proliferation[8]. The combination has shown therapeutic synergism in preclinical models and has been evaluated in phase I clinical trials for patients with metastatic or unresectable solid tumors[3][4]. Both drugs are primarily administered intravenously.
- Brand names
- Jevtana (for cabazitaxel)Platinol (for cisplatin)
02
Targets
DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on cabazitaxel + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cabazitaxel + cisplatin.